Welcome to our dedicated page for GEMINA LABORATORIES news (Ticker: GLABF), a resource for investors and traders seeking the latest updates and insights on GEMINA LABORATORIES stock.
Gemina Laboratories Ltd (GLABF) is a leader in biosensor diagnostics, developing rapid testing platforms through proprietary chemistry innovations. This page provides real-time access to official announcements and verified updates about the company’s strategic initiatives.
Investors and industry observers will find comprehensive coverage of earnings reports, R&D breakthroughs, and commercial partnerships. Our curated feed includes regulatory filings, technology licensing deals, and expansion updates across global markets.
Key focus areas include advancements in lateral flow diagnostics, collaborations with healthcare institutions, and production facility developments. All content is sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page to stay informed about GLABF’s progress in creating cost-effective diagnostic solutions and expanding presence on the CSE, OTCQB, and Frankfurt exchanges.
Gemina Laboratories (CSE:GLAB, OCTQB:GLABF) has announced a non-brokered private placement offering of up to 9,333,333 common shares at $0.75 per share, aiming to raise gross proceeds of up to $7,000,000. The funds will be used to accelerate platform development, expand production, support business development and commercialization activities, and provide working capital. The securities issued will have a four-month and one-day statutory hold period in Canada.
Gemina Laboratories has provided a strategic update for H1 2024, highlighting key achievements and future plans. The company signed its first license deal with a global diagnostics company in April, signaling commercial validation. It is also in advanced discussions with four other significant diagnostics firms. In June, Gemina issued its first commercial invoice, with revenues expected to ramp up in 2025. The company continues to innovate, with a strong R&D team developing new products and solutions. Gemina's new protein production facility is set to open in August, and the company has expanded its market presence to the U.S. by listing on the OTCQB under ticker GLABF.
Gemina Laboratories (OTCQB: GLABF) has commenced trading on the OTCQB Venture Market in the United States. This move aims to expand the company's investor reach, build visibility, increase liquidity, and diversify its shareholder base. Gemina's shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol 'GLAB' and the Frankfurt Exchange under '817'. CEO Brian Firth is optimistic that this expansion will complement their existing listings and facilitate a streamlined approach for US investors to trade their shares. Investors can access real-time quotes and financial disclosures on the OTC Markets website.
Gemina Laboratories Ltd. (CSE:GLAB, OTC:GLABF) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. CEO Brian Firth will present both virtually and in-person, with the presentation available online starting at 7:00 a.m. EST. Gemina specializes in biosensor technology and diagnostics, focusing on rapid testing for pathogens affecting health, including COVID-19. A replay of the presentation will be accessible for 30 days.
Gemina Laboratories Ltd. (CSE:GLAB, OTC:GLABF) has appointed Brian Firth as its new Chief Executive Officer, transitioning from an R&D focus to a revenue-driven model. Firth, with extensive experience in point-of-care diagnostics, previously held leadership roles at Swiss Precision Diagnostics and founded The Health Works Ltd. His appointment is viewed as a significant step towards growth, with plans to launch revenue-generating products. Concurrently, founding CEO John Davies becomes Chairman of the Board. Firth's stock options include performance milestones and a vesting schedule starting September 7, 2023.
